Using quality of life measures in a phase i clinical trial of noni in patients with advanced cancer to select a phase II dose

Journal of Dietary Supplements

Volumn 6, Issue 4, 2009, Pages 347-359

  Issell, Brian F ^a   Gotay, Carolyn C ^b   Pagano, Ian ^c   Franke, Adrian A ^c  

^a SCRIPPS HEALTH   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Noni; Phase I; QOL

Indexed keywords

PLANT EXTRACT; SCOPOLETIN;

ANALGESIA; ARTICLE; CHEMISTRY; DAILY LIFE ACTIVITY; DOSE RESPONSE; FATIGUE; HUMAN; METABOLISM; MORINDA; NEOPLASM; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHYTOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

ACTIVITIES OF DAILY LIVING; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; HUMANS; MORINDA; NEOPLASMS; PAIN; PAIN MANAGEMENT; PHYTOTHERAPY; PLANT EXTRACTS; QUALITY OF LIFE; QUESTIONNAIRES; SCOPOLETIN; SEVERITY OF ILLNESS INDEX;

MORINDA CITRIFOLIA;

EID: 70749128855     PISSN: 19390211     EISSN: None     Source Type: Journal    
DOI: 10.3109/19390210903280272     Document Type: Article

References (18)

1. Aaronson NK, Ahmedzai S, BullingerM, Crabeels CD, Estape J, Filiberti A, Flechtner H, Frick U, Hurny C, Kaasa S, Klee M, Mastilica M, Osoba D, Pfausler B, Rajavi D, Rofe PBC, Schraub S, Sullivan M, Takeda F. The EORTC core quality of life questionnaire: Interim results of an international field study. In: D Osoba (Ed.), Effect of cancer on quality of life, pp. 185-203.
2. Boca Raton, FL: CRC Press, 1991. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub, S, Sneeuw, K, SullivanM, Takeda F. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
3. Aaronson NK, Cull A, Kaasa S, Sprangers MAG. The European organization for research and treatment of cancer (EORTC) modular approach to quality of life assessment in oncology: An update. In: B Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Raven Press, 1995. A Manual for Participants in Clinical Trials of Investigational Agents sponsored by DCTO, NCI. http://ctep.cancer.gov.
4. Chang YJ, Lee JS, Lee CG, Lee WS, Lee KS, Bang SM, Wang XS, Mendoza TR, Cleeland CS, Yun YH. Assessment of clinical relevant fatigue level in cancer. Support Care Cancer. 2007;15(7):891-896.
5. Dixon AR, McMillen H, Etkin NL. Ferment this: The transformation of noni, a traditional polynesian medicine (Morinda Citrifolia, Rubiaceae). Econ Bot. 1999;53(1):51-68.
6. Hiramatsu T, Imoto M, Koyano T, Umezawa K. Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia. Cancer Lett. 1993;73:161-166.
7. Hirazumi A, Furusawa E. An immunomodulatory polysaccharide-rich substance from the fruit juice of Morinda citrifolia (noni) with antitumor activity. Phytother Res. 1999;13:380-387.
8. Hiwasa T, Arase Y, Chen Z, Kita K, Umezawa K, Ito H, Suzuki N. Stimulation of ultraviolet-induced apoptosis of human fibroblast UV-r 1 cells by tyrosine kinase inhibitors. FEBS Lett. 1999;444:173-176.
9. Hornick CA, Myers A, Sadowska-Krowicka H, Anthony CT, Woltering EA. Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice from Morinda citrifolia (noni). Angiogenesis. 2003;6:143-149. http://ctep.cancer.gov. http://groups.eortc.be/qol/ questionnaires-qlqc30.htm
10. Issell BF, Franke A, Fielding RM. Pharmacokinetic study of noni fruit extract. J Diet Suppl. 2008;5:373-382.
11. Liu G, Bode A, Ma W, Sang S, Ho C, Dong Z. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res. 2001a;61:5749-5756.
12. Liu X, Zhang L, Fu XL, Chen K, Qian BC. Effect of scopoletin on PC-3 cell proliferation and apoptosis. Acta Pharmacol Sin. 2001b;10:929-933.
13. McClatchey W. From polynesian healers to health food stores: Changing perspectives of Morinda citrifolia (Rubiaceae). Integr Cancer Ther. 2002;1(2):110-120.
14. Mendoza T,Wang XS, Cleeland CS, MorrisseyM, Johnson BA,Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
15. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592.
16. Osoba D, RodriguesG,Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
17. Tahitian noni brochure replaced by Solomon N. Noni Juice, How Much, How Often, For What. Direct Source Publishing 2004.
18. Wang M, Best BJ, Jensen CJ, Nowicki D, Palu AK, Anderson G. Morinda citrifolia (noni): A literature review and recent advances in Noni research. Acta Pharmacol. Sin. 2002;23(12):1127-1141.